2019-10-10
Harvard University has recently signed an agreement with the biotech company of Moderna to develop mRNA technologies for use in the treatment of immunological diseases. The establishment of an initiative called ARTiMIS is one of the successful outcomes of this collaboration, which provides Harvard researchers with the opportunity to access Moderna’s mRNA platform and use it for supporting drug...
2019-08-30
2019-08-28
